Background
Phase III RCT (Argentinian/CECOG Trial). 515 patients with FIGO stage IIB–IVA cervical carcinoma with negative para-aortic lymph nodes on CT. International multicenter study. Tested whether adding gemcitabine to concurrent cisplatin chemoradiation, followed by adjuvant gemcitabine+cisplatin chemotherapy, improved outcomes beyond standard weekly cisplatin chemoradiation.
Interventions and follow up
Arm A: Pelvic RT (50.4 Gy) + concurrent cisplatin 40 mg/m² weekly + gemcitabine 125 mg/m² weekly × 6 weeks, then adjuvant gemcitabine 1,000 mg/m² d1,8 + cisplatin 50 mg/m² d1 q3wk × 2 cycles + brachytherapy
Arm B: Pelvic RT (50.4 Gy) + concurrent cisplatin 40 mg/m² weekly × 6 weeks + brachytherapy (standard arm)
Primary endpoint: Overall survival
mFollow up: Median ~3 year
Arm B: Pelvic RT (50.4 Gy) + concurrent cisplatin 40 mg/m² weekly × 6 weeks + brachytherapy (standard arm)
Primary endpoint: Overall survival
mFollow up: Median ~3 year
Results
3-year OS: 74.8% GemCis vs 65.8% Cis, HR 0.68 (95% CI 0.49–0.95), P=.022
3-year PFS: 74.4% vs 65.0%, HR 0.68, P=.029
3-year PFS: 74.4% vs 65.0%, HR 0.68, P=.029
Adverse events
Main adverse events: Grade 3–4 toxicity significantly higher in GemCis arm. Grade 3–4 leukopenia: 87% vs 13%. Grade 3–4 renal toxicity: 7% vs 1%. Treatment-related deaths: 2 (GemCis) vs 0 (Cis). Significantly more dose reductions and treatment delays in GemCis arm. Grade 3–4 febrile neutropenia: 16% vs 1%.
Conclusions
Adding gemcitabine to concurrent cisplatin chemoradiation followed by adjuvant gemcitabine-cisplatin significantly improved 3-year OS and PFS in locally advanced cervical cancer. However, the substantial increase in grade 3–4 toxicity — particularly severe myelosuppression — has limited widespread adoption of this regimen.
Key Limitations
Key Limitations: The degree of additional toxicity (87% vs 13% grade 3–4 leukopenia) is extreme and raises serious safety concerns for routine use. Adjuvant component makes it impossible to separate the contribution of the gemcitabine concurrent component from the adjuvant cycles. This regimen has not been widely adopted in practice due to toxicity concerns, and was not included in major NCCN or ESMO guidelines as preferred. A subsequent meta-analysis suggested benefit is real but the risk-benefit ratio remains debated. No long-term quality-of-life data reported.
Clinical Context
Despite showing an OS benefit, the GemCis regimen from this trial has not replaced weekly cisplatin as standard of care due to its toxicity burden. Ongoing efforts focus on adding immunotherapy to the cisplatin-RT backbone (e.g., KEYNOTE-A18 adding pembrolizumab to cisplatin CRT showed improved PFS and OS in 2024). Adjuvant chemotherapy after CRT in locally advanced cervical cancer is being evaluated in the ongoing OUTBACK and INTERLACE trials.
References